Soru

Zorluk: ZorGastroenterology and Hepatology

A 6262-year-old man with a history of alcohol-associated cirrhosis and hepatic encephalopathy is evaluated on hospital day 44. He was initially admitted for fever, worsening confusion, and diffuse abdominal pain. On admission, diagnostic paracentesis revealed an ascitic fluid absolute neutrophil count of 750/mm3750/\text{mm}^3, consistent with spontaneous bacterial peritonitis (SBP). Because the patient had been hospitalized three weeks prior for a variceal bleed, empiric therapy was initiated with intravenous piperacillin-tazobactam, and he was given intravenous albumin. Today, his temperature is 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure is 112/68 mm Hg112/68\text{ mm Hg}, and pulse is 78/min78/\text{min}. He is alert, oriented, and reports that his abdominal pain has completely resolved. Ascitic fluid cultures drawn on admission have grown *Escherichia coli*. Susceptibility testing demonstrates that the organism is susceptible to ceftriaxone, cefotaxime, ciprofloxacin, and piperacillin-tazobactam; it is resistant to ampicillin. Which of the following is the most appropriate next step in the pharmacologic management of this patient's infection?

  1. Transition to intravenous ceftriaxoneCevap
  2. B
    Continue intravenous piperacillin-tazobactam
  3. C
    Transition to intravenous meropenem
  4. D
    Add intravenous metronidazole to the current regimen
  5. E
    Transition to oral rifaximin

Cevap

Transition to intravenous ceftriaxone
The correct approach is to transition to intravenous ceftriaxone. This patient developed spontaneous bacterial peritonitis (SBP) and was appropriately started on broad-spectrum empiric therapy (piperacillin-tazobactam) due to his recent healthcare exposure (hospitalization three weeks prior), which placed him at higher risk for resistant organisms. However, once culture and susceptibility data are available, strict antimicrobial stewardship principles dictate de-escalating to the narrowest-spectrum effective agent. The isolate is *E. coli* that is highly susceptible to ceftriaxone. Ceftriaxone, a third-generation cephalosporin, provides excellent targeted coverage for this pathogen without unnecessarily exposing the patient to the broader anaerobic and anti-pseudomonal coverage of piperacillin-tazobactam. De-escalation minimizes the risk of adverse effects, reduces healthcare costs, and limits the development of antimicrobial resistance.

Adım Adım Çözüm

1
Evaluate the initial diagnosis and empiric therapy.
The patient has healthcare-associated spontaneous bacterial peritonitis (SBP) and was correctly started on broad-spectrum empiric therapy (piperacillin-tazobactam) due to his recent hospitalization.
Recent healthcare exposure increases the risk of resistant pathogens, justifying initial broad-spectrum coverage.
2
Analyze the patient's clinical trajectory and new laboratory data.
The patient has clinically improved (afebrile, resolved pain, alert), and the ascitic fluid culture shows E. coli susceptible to ceftriaxone, cefotaxime, and ciprofloxacin.
Clinical improvement confirms the infection is being effectively treated, and susceptibility data provides a roadmap for targeted therapy.
3
Apply the principles of antimicrobial stewardship.
Therapy should be de-escalated to intravenous ceftriaxone.
De-escalating from a broad-spectrum agent (piperacillin-tazobactam) to a narrower, effective agent (ceftriaxone) minimizes toxicity, reduces healthcare costs, and prevents the emergence of multidrug-resistant organisms and C. difficile.

Anahtar Kavram

Antimicrobial stewardship dictates that empiric broad-spectrum antibiotic therapy for spontaneous bacterial peritonitis (SBP) should be de-escalated to the narrowest-spectrum effective agent once culture and susceptibility data become available.
Bu soruyu puanla